Trials / Completed
CompletedNCT04559581
Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 425 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary objective is to evaluate the incidence of adverse drug reactions (focus on hepatic function disorders) of Ofev Capsules under the real world setting in patients with Chronic fibrosing Interstitial Lung Diseases with a progressive phenotype (PF-ILD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | Ofev Capsules as prescribed by the treating physician |
Timeline
- Start date
- 2020-10-02
- Primary completion
- 2024-12-18
- Completion
- 2025-01-22
- First posted
- 2020-09-23
- Last updated
- 2026-02-06
- Results posted
- 2026-02-06
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04559581. Inclusion in this directory is not an endorsement.